Artificial Intelligence in Mammography Screening in Norway

ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age50-69
SponsorNorwegian Institute of Public Health

About this trial

The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.

Eligibility criteria

Qualifiers

Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent

Disqualifiers

Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent

Trial design

Treatments tested in this trial

  • AI assisted mammography screening interpretation
  • Standard mammography screening interpretation

Treatment groups

150,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Norwegian Institute of Public Health

Lead sponsor

Helse Vest

Collaborator

Helse Midt-Norge

Collaborator

Helse Nord

Collaborator

Norwegian Cancer Society

Collaborator